Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 6/20 | 0.41 |
| ▸ | TK1 | P04183 | 5/20 | 0.38 |
| ▸ | NT5M | Q9NPB1 | 1/20 | 0.38 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.37 |
| ▸ | TK2 | O00142 | 3/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5188453 | 1.00 | TOP2A (0.41) | TOP2ATK1NT5MRNASE1TK2 | |
| SCHEMBL12942597 | 1.00 | TOP2A (0.41) | TOP2ATK1NT5MRNASE1TK2 | |
| SCHEMBL25401296 | 0.91 | LMNA (0.34) | TOP2A | |
| SCHEMBL5191057 | 0.86 | TOP2A (0.41) | TOP2ATK1NT5MRNASE1TK2 | |
| SCHEMBL12942598 | 0.86 | TOP2A (0.41) | TOP2ATK1NT5MRNASE1TK2 | |
| SCHEMBL5191053 | 0.86 | TOP2A (0.41) | TOP2ATK1NT5MRNASE1TK2 | |
| SCHEMBL15354281 | 0.85 | TOP2A (0.40) | TOP2ATK1NT5MRNASE1TK2 | |
| SCHEMBL8772040 | 0.85 | TOP2A (0.41) | TOP2ATK1NT5MRNASE1TK2 | |
| SCHEMBL8772035 | 0.85 | TOP2A (0.41) | TOP2ATK1NT5MRNASE1TK2 | |
| SCHEMBL8772065 | 0.84 | TOP2A (0.40) | TOP2ATK1NT5MRNASE1TK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1287012-B1 | NUCLEOTIDE ANALOGUES COMPRISING A REPORTER MOIETY AND A POLYMERASE ENZYME BLOCKING MOIETY | GE HEALTHCARE UK LTD (GB) | 2007-07-25 | — | — | EP | disclosed |
| US-7078499-B2 | Nucleotide analogues comprising a reporter moiety and a polymerase enzyme blocking moiety | GE HEALTHCARE UK LIMITED (GB) | 2006-07-18 | — | — | US | disclosed |
| US-20030194722-A1 | Nucleotide analogues comprising a reporter moiety and a polymerase enzyme blocking moiety | GE HEALTHCARE UK LIMITED (GB) | 2003-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030194722-A1 | Nucleotide analogues comprising a reporter moiety and a polymerase enzyme blocking moiety | POLB, POLA1, XRN2 | TOP2A 78/4885TK1 56/4885NT5M 3021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.